article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

The selections feature topics ranging from an analysis of government and industry investments for recently approved drugs, to a discussion of court decisions on mifepristone, and an examination of the added therapeutic benefit associated with the top-selling brand-name drugs in Medicare. JAMA Health Forum. PMID: 37115539).

article thumbnail

California Enters Insulin Manufacturing: Can We Expect to See a California Effect?

Bill of Health

By Aparajita Lath For over 100 years, policy makers and pharmaceutical manufacturers in the U.S. have debated whether the government should produce drugs and biologics. Until now, private industry has largely won– but that may be changing, due to a recent California initiative. Now, the tide is turning.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Prescription Drugs: From Costs and Bad Reputation to Civica Rx and Amazon to the Rescue

Health Populi

health consumers believe that Medicare should be allowed to negotiate with drug companies to fetch lower prices for prescription drugs, and that more drugs should switch to generic when possible. consumers have long-ranked the pharmaceutical industry relatively low, but above car salespeople and the Federal government.

article thumbnail

Health Provider News

Hall Render

NATIONAL 6 health systems using GPT and AI tools 100,000 nurses left industry during the pandemic, report finds AHA backs bill to delay Medicaid DSH cuts by 2 years AHA launches info hub for healthcare quality leaders AHA opposes MedPAC recommendations to Congress on site-neutral, Part B drug, wage index policies AHA ramps up 340B protection efforts (..)

article thumbnail

Slip Slidin’ Away: the Reputations of Pharma and Healthcare in the U.S. Decline in the Latest Gallup Poll

Health Populi

At the very bottom of the list is the pharmaceutical industry, with net 60% of people feeling negative about pharma (28% somewhat negative + 32% feeling very negative). Nonetheless, there is not a lot of love for the pharma industry right now in the second half of 2023. With tri-partisan support among U.S.

article thumbnail

Thinking Pharma on a Friday: Europe’s Big Reforms for a Health Union & the U.S. 50-State Fragments

Health Populi

On 26th April 2023, the EC unveiled the most significant reforms for the region’s pharmaceutical industry in twenty years. For several years, nearly as many Republicans as Democrats have been looking to government to pass legislation allowing Medicare to negotiate drug prices with pharmaceutical companies.